adalimumab-atto (Amjevita) vs golimumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab-atto (Amjevita)
Marketed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
golimumab · Simponi
Marketed by Johnson & Johnson
NCT01863771 · Phase 3 · completed
Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).
Reported efficacy
Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)
Result source: NCT01863771
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-atto (Amjevita) | golimumab |
|---|---|---|
| Clinical remission (induction) | —Not reported | 17.9% vs 6.4%+11.5 vs placeboNCT004875391 other result
|
| Clinical remission (maintenance) | —Not reported | —Trial running · NCT03596645 |
| Clinical response (induction) | —Not reported | 54.9% vs 30.3%+24.6 vs placeboNCT004875391 other result
|
| Endoscopic improvement (induction) | —Not reported | —Trial running · NCT03596645 |
| Corticosteroid-free remission (maintenance) | —Not reported | 23.2% vs 18.4%+4.8 vs placeboNCT004886311 other result
|
Clinical remission (induction)
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- 17.9% vs 6.4%+11.5 vs placeboNCT00487539
1 other result
- 17.8% vs 6.4% NCT00487539
Clinical remission (maintenance)
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- —Trial running · NCT03596645
Clinical response (induction)
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- 54.9% vs 30.3%+24.6 vs placeboNCT00487539
1 other result
- 51% vs 30.3% NCT00487539
Endoscopic improvement (induction)
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- —Trial running · NCT03596645
Corticosteroid-free remission (maintenance)
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- 23.2% vs 18.4%+4.8 vs placeboNCT00488631
1 other result
- 28.2% vs 18.4% NCT00488631
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
adalimumab-atto (Amjevita): no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab-atto (Amjevita): 0 of 4 rows · golimumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | golimumab |
|---|---|
| Dropout rate | —100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.6%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 29.2%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 53.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 44.8%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 27.9%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 1.2%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.9%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 7.1%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 4.3%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 23.7% NCT02318667 · Phase 4 · registry result, not featured evidence 17.1% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 6.9%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | —100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.3%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 7.8%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 12.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 13%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 7.8%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 0.3%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 2.8%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 —Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence —Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 2.6% NCT02318667 · Phase 4 · registry result, not featured evidence 3.4% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 3.1%100 mga NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results10%100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 3.5%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.3%200 mg NCT00488631 · Phase 3 14.3%100 mg NCT00488631 · Phase 3 · combination 7.1%100 mg - 200 mg NCT00488631 · Phase 3 15.6%100 mg NCT00488631 · Phase 3 · monotherapy 0%100 mg - 200 mg NCT00488631 · Phase 3 19.4%100 mg NCT00488631 · Phase 3 14.8%100 mg NCT00488631 · Phase 3 · monotherapy 25%100 mg NCT00488631 · Phase 3 8.4%50 mg NCT00488631 · Phase 3 · combination 24%50 mg - 100 mg NCT00488631 · Phase 3 5.3%50 mg - 100 mg NCT00488631 · Phase 3 11.8%50 mg NCT00488631 · Phase 3 0%50 mg NCT00488631 · Phase 3 4.5%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 9.5%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 0%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence 23.9% NCT02092285 · Phase 4 · registry result, not featured evidence 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 4.5%Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 100 mga nasopharyngitis 53.1% (placebo 22.6%) injection site erythema 15.6% (placebo 0%) influenza 12.5% (placebo 3.2%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 26 more results100 mg nasopharyngitis 23.3% (placebo 22.6%) colitis ulcerative 6.7% (placebo 6.5%) upper respiratory tract inflammation 6.7% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 11.8% (placebo 22.6%) colitis ulcerative 4.9% (placebo 6.5%) injection site erythema 3.5% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 200 mg colitis ulcerative 28.6% (placebo 18.6%) gastroenteritis viral 28.6% (placebo 0%) nasopharyngitis 28.6% (placebo 6.4%) NCT00488631 · Phase 3 100 mg nasopharyngitis 14.9% (placebo 6.4%) colitis ulcerative 11.7% (placebo 18.6%) headache 7.8% (placebo 9%) NCT00488631 · Phase 3 · combination 100 mg - 200 mg nasopharyngitis 21.4% (placebo 6.4%) headache 14.3% (placebo 9%) viral upper respiratory tract infection 14.3% (placebo 0%) NCT00488631 · Phase 3 100 mg colitis ulcerative 12.1% (placebo 18.6%) nasopharyngitis 8.1% (placebo 6.4%) arthralgia 7.2% (placebo 7.1%) NCT00488631 · Phase 3 · monotherapy 100 mg - 200 mg colitis ulcerative 30% (placebo 18.6%) diarrhoea 20% (placebo 4.5%) gastroenteritis 20% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 23.7% (placebo 18.6%) nasopharyngitis 16.4% (placebo 6.4%) sinusitis 9% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 10.9% (placebo 18.6%) headache 9.6% (placebo 9%) nasopharyngitis 7.4% (placebo 6.4%) NCT00488631 · Phase 3 · monotherapy 100 mg colitis ulcerative 25% (placebo 18.6%) nasopharyngitis 14.3% (placebo 6.4%) arthralgia 10.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg colitis ulcerative 16.2% (placebo 18.6%) nasopharyngitis 9.1% (placebo 6.4%) headache 8.4% (placebo 9%) NCT00488631 · Phase 3 · combination 50 mg - 100 mg nasopharyngitis 16% (placebo 6.4%) pyrexia 16% (placebo 4.5%) upper respiratory tract infection 12% (placebo 2.6%) NCT00488631 · Phase 3 50 mg - 100 mg colitis ulcerative 10.5% (placebo 18.6%) dyspepsia 10.5% (placebo 1.3%) upper respiratory tract infection 10.5% (placebo 2.6%) NCT00488631 · Phase 3 50 mg colitis ulcerative 18.3% (placebo 18.6%) nasopharyngitis 10.8% (placebo 6.4%) arthralgia 9.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg abdominal pain 100% (placebo 2.6%) abdominal pain upper 100% (placebo 0.6%) bite 100% (placebo 0%) NCT00488631 · Phase 3 400 mg -> 200 mg headache 4.5% (placebo 5.2%) nausea 3.6% (placebo 1.8%) pyrexia 3% (placebo 2.1%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 200 mg -> 100 mg nasopharyngitis 3.9% (placebo 3.6%) headache 3.3% (placebo 5.2%) anaemia 2.4% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 100 mg -> 50 mg headache 7% (placebo 5.2%) injection site erythema 4.2% (placebo 0%) anaemia 2.8% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 colitis ulcerative 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence colitis ulcerative 13.7% nasopharyngitis 9.8% colitis 7.3% NCT02092285 · Phase 4 · registry result, not featured evidence anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 11.1% anaemia 6.9% upper respiratory tract infection 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 7.5% anaemia 3% headache 3% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 5.2% anaemia 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
golimumab
show 4 more results
show 2 more results
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-atto (Amjevita)
Marketed by Amgen
NCT01970475 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).
Reported efficacy
Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)
Result source: NCT01970475
golimumab · Simponi
Marketed by Johnson & Johnson
NCT00264537 · Phase 3 · completed
This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.
Reported efficacy
ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)
Result source: NCT00264550
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab-atto (Amjevita) | golimumab |
|---|---|---|
| ACR20 | 74.6% vs 72.4%vs AdalimumabNCT019704752 other results
| 44.4% vs 33.1%+11.3 vs placeboNCT0026455025 other results
|
| ACR50 | 49.2% vs 52%vs AdalimumabNCT01970475 | 32.7% vs 29.4%+3.3 vs placeboNCT0026453719 other results
|
| ACR70 | 26% vs 22.9%vs AdalimumabNCT01970475 | 16.1% vs 25.9%vs GolimumabNCT01715896 |
| DAS28-CRP remission | —Not reported | —Trial running · NCT03414502 |
| HAQ-DI, change | —Not reported | 0.1 vs 0.1±0 vs placeboNCT002645508 other results
|
| Modified Sharp score, change | —Not reported | 1.3 vs 1.4−0.1 vs placeboNCT0026453711 other results
|
ACR20
- adalimumab-atto (Amjevita)
- 74.6% vs 72.4%vs AdalimumabNCT01970475
2 other results
- 63.5% vs 62.5% NCT01970475
- 35.4% vs 24.5% NCT01970475
- golimumab
- 44.4% vs 33.1%+11.3 vs placeboNCT00264550
25 other results
- 36.5% vs 18% NCT00299546
- 40.9% vs 15.9% NCT01248780
- 34.7% vs 18% NCT00299546
- 58.5% vs 24.9% NCT00973479
- 56.2% vs 33.1% NCT00264550
- 55.1% vs 33.1% NCT00264550
- 51.6% vs 49.4% NCT00264537
- 35.3% vs 27.8% NCT00264550
- 42.6% vs 16% NCT00299546
- 42.4% vs 15.9% NCT01248780
- 31.3% vs 16% NCT00299546
- 48.1% vs 27.9% NCT00361335
- 39.8% vs 27.9% NCT00361335
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 59.6% vs 27.8% NCT00264550
- 59.6% vs 27.8% NCT00264550
- 51.6% vs 27.9% NCT00361335
- 55% vs 27.9% NCT00361335
- 55.9% vs 37.1% NCT00207714
- 79.4% vs 37.1% NCT00207714
- 60% vs 37.1% NCT00207714
- 50% vs 37.1% NCT00207714
- 62% vs 65.6% NCT01715896
ACR50
- adalimumab-atto (Amjevita)
- 49.2% vs 52%vs AdalimumabNCT01970475
- golimumab
- 32.7% vs 29.4%+3.3 vs placeboNCT00264537
19 other results
- 19.4% vs 13.2% NCT00361335
- 12.5% vs 13.2% NCT00361335
- 36.5% vs 29.4% NCT00264537
- 40.3% vs 29.4% NCT00264537
- 21.1% vs 13.2% NCT00361335
- 21.7% vs 13.2% NCT00361335
- 38.4% vs 29.4% NCT00264537
- 18.2% vs 6.7% NCT00299546
- 15% vs 6.7% NCT00299546
- 34.9% vs 13.2% NCT00973479
- 28.9% vs 35.8% NCT00264537
- 11.6% vs 9.3% NCT00361335
- 8.6% vs 9.3% NCT00361335
- 44.6% vs 35.8% NCT00264537
- 44.2% vs 35.8% NCT00264537
- 25% vs 9.3% NCT00361335
- 18.6% vs 9.3% NCT00361335
- 44.4% vs 35.8% NCT00264537
- 34.8% vs 43.4% NCT01715896
ACR70
- adalimumab-atto (Amjevita)
- 26% vs 22.9%vs AdalimumabNCT01970475
- golimumab
- 16.1% vs 25.9%vs GolimumabNCT01715896
DAS28-CRP remission
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- —Trial running · NCT03414502
HAQ-DI, change
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- 0.1 vs 0.1±0 vs placeboNCT00264550
8 other results
- 0.5 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- 0.3 vs 0.1 NCT00264550
- -0.3 vs 0.2 NCT01248780
- 0.5 vs 0.1 NCT00973479
- 0.4 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- -0.4 vs -0.6 NCT01715896
Modified Sharp score, change
- adalimumab-atto (Amjevita)
- —Not reported
- golimumab
- 1.3 vs 1.4−0.1 vs placeboNCT00264537
11 other results
- 0.1 vs 1.4 NCT00264537
- 0.7 vs 1.4 NCT00264537
- 0.4 vs 1.4 NCT00264537
- 2.2 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0.2 vs 2.2 NCT00264537
- 1.3 vs 2.2 NCT00264537
- 0.0 vs 1.1 NCT00973479
- 0.7 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0 vs 0 NCT00264550
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. adalimumab-atto (Amjevita): 5 of 5 rows · golimumab: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab-atto (Amjevita) | golimumab Rows use multiple source trials |
|---|---|---|
| DAS28-CRP absolute change · score | -2.32 vs -2.32 Adalimumab score @ 24wka,b,c,d NCT01970475 · Phase 3 | -2.11 vs -2.4 Golimumab score @ 24.14wk100 mga,b,c,d NCT01715896 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 8%e NCT01970475 · Phase 3 | 36.5%100 mg + placeboe NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 37.7%100 mg + methotrexate NCT00264537 · Phase 3 · combination 31.4%50 mg + methotrexate NCT00264537 · Phase 3 · combination 30.8%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 33.7%100 mg + MTX NCT00264550 · Phase 3 · combination 19.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 17.5%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 11.4%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 56.2%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 60.1%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 8.3%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 15.7%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 23.5%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.7%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 20%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 29.4%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 2.7%e NCT01970475 · Phase 3 | 20.1%100 mg + placeboe NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 21.4%100 mg + methotrexate NCT00264537 · Phase 3 · combination 15.1%50 mg + methotrexate NCT00264537 · Phase 3 · combination 13.5%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 15.7%100 mg + MTX NCT00264550 · Phase 3 · combination 10.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 8.1%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 5.3%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 17.6%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 14.4%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 4.5%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 8.8%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 2.9%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 5.7%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 11.8%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3.8%e NCT01970475 · Phase 3 | —100 mg + placeboe NCT00264537 · Phase 3 show 35 more results38.7%100 mg SC NCT00264537 · Phase 3 32%50 mg SC NCT00264537 · Phase 3 —100 mg + methotrexate NCT00264537 · Phase 3 · combination —50 mg + methotrexate NCT00264537 · Phase 3 · combination —100 mg + placebo NCT00264550 · Phase 3 45.7%100 mg SC injections NCT00264550 · Phase 3 31.4%50 mg SC injections NCT00264550 · Phase 3 —100 mg + MTX NCT00264550 · Phase 3 · combination —50 mg + MTX NCT00264550 · Phase 3 · combination 4.4%50mg SC NCT01004432 · Phase 3 · combination 2.7%50 mg SC NCT01004432 · Phase 3 · combination 4.6%50 mg SC NCT01004432 · Phase 3 · combination 4.7%50 mg SC NCT01004432 · Phase 3 · combination 5.4%2mg/kg IV NCT01004432 · Phase 3 · combination 19.7%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 6.1%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination 33.3%100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —100 mg NCT00299546 · Phase 3 · registry result, not featured evidence 34.7%50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 6%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 2.7%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 6.9%2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination 6.8%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence 6.3%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 13.3%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 9.1%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 14%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 13.7%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2.9%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 15.2%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.3%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 18.9%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 15.6%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 26 more results50 mg SC upper respiratory tract infection 26.2% alanine aminotransferase increased 18% bronchitis 15.1% NCT00264537 · Phase 3 100 mg SC injections upper respiratory tract infection 34.8% cough 19% nasopharyngitis 19% NCT00264550 · Phase 3 50 mg SC injections upper respiratory tract infection 37.1% cough 22.9% bronchitis 17.1% NCT00264550 · Phase 3 50 mg SC upper respiratory tract infection 9.3% depression 5.3% sinusitis 5.3% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.7% headache 5.5% urinary tract infection 5.5% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.1% urinary tract infection 6.1% sinusitis 5.7% NCT01004432 · Phase 3 · combination 2mg/kg IV upper respiratory tract infection 8.2% sinusitis 7.1% bronchitis 6% NCT01004432 · Phase 3 · combination 2 mg/kg + MTX upper respiratory tract infection 13.7% bronchitis 9.4% rheumatoid arthritis 8.4% NCT00973479 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 19.1% liver function test abnormal 6.1% anaemia 1.5% NCT01248780 · Phase 3 · registry result, not featured evidence · combination 100 mg SC injections upper respiratory tract infection 31.2% nasopharyngitis 18.8% rheumatoid arthritis 16.7% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg SC injections upper respiratory tract infection 25.5% sinusitis 19.4% headache 14.3% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 0% upper respiratory tract infection 0% NCT00975130 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 7.1% upper respiratory tract infection 2.4% NCT00975130 · Phase 3 · registry result, not featured evidence 2 mg/kg intravenous + 50 mg subcutaneous upper respiratory tract infection 6.1% nasopharyngitis 5.3% NCT00975130 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 8.5% (placebo 9.3%) nasopharyngitis 7.7% (placebo 5.4%) rheumatoid arthritis 5.1% (placebo 4.7%) NCT00361335 · Phase 3 · registry result, not featured evidence 4 mg/kg upper respiratory tract infection 12.6% (placebo 9.3%) rheumatoid arthritis 9.4% (placebo 4.7%) bronchitis 6.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 2 mg/kg rheumatoid arthritis 15.6% (placebo 4.7%) upper respiratory tract infection 10.9% (placebo 9.3%) bronchitis 7.8% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 50 mg upper respiratory tract infection 7.2% (placebo 9.3%) rheumatoid arthritis 6.9% (placebo 4.7%) bronchitis 5.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 4 mg/kg upper respiratory tract infection 12.2% (placebo 9.3%) nausea 10.7% (placebo 7%) bronchitis 7.7% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2 mg/kg upper respiratory tract infection 12.1% (placebo 9.3%) nausea 11% (placebo 7%) headache 9.3% (placebo 10.1%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 100 mg nasopharyngitis 5.7% headache 4.3% hepatic enzyme increased 4.3% NCT01715896 · Phase 2 · registry result, not featured evidence 100 mg every 4 weeks headache 27.3% (placebo 20.6%) nausea 21.2% (placebo 5.9%) upper respiratory tract infection 15.2% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence 100 mg every 2 or 4 weeks injection site erythema 28.6% (placebo 11.8%) nasopharyngitis 22.9% (placebo 8.8%) nausea 22.9% (placebo 5.9%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 4 weeks headache 21.6% (placebo 20.6%) nasopharyngitis 21.6% (placebo 8.8%) rheumatoid arthritis 21.6% (placebo 14.7%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 2 or 4 weeks nausea 25% (placebo 5.9%) rheumatoid arthritis 21.9% (placebo 14.7%) headache 18.8% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 24.14 weeks versus 24 weeks.
- ePopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
golimumab
show 11 more results
show 4 more results
show 8 more results
show 3 more results
show 6 more results
show 3 more results
show 3 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
+ 34 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · golimumab's landscape